skip to content

Collaboration and Impact


We work hard at translating our basic research into company success stories.

Read more at: Solexa Sequencing

Solexa Sequencing

An after-work beer at the Panton Arms was the start of a DNA revolution.

Read more at: Xampla


Xampla's goal is to eradicate the need for single-use plastics.

Read more at: PharmEnable


PharmEnable uses advanced medicinal chemistry and artificial intelligence to design potential drug therapies.

Read more at: Aqdot


Aqdot has revolutionised the encapsulation market.

Read more at: Astex


Astex' fragment-based approach to the discovery of small molecule drugs is used by many major pharma companies.

Read more at: Fluidic Analytics

Fluidic Analytics

Fluidic Analytics is changing the way that protein analysis is conducted in industrial, academic and clinical settings.

Read more at: Sphere Fluidics

Sphere Fluidics

Sphere Fluidics' microdroplet technology is set to automate the discovery of therapeutic monoclonal antibodies, and transform how the biopharmaceutical industry works in this area.

Read more at: Early stage spin-outs

Early stage spin-outs

University programmes like Cambridge Enterprise and Accelerate are helping us to spin-out and nurture the ideas of our researchers and students into beneficial and practicable applications.